Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • BioLife Solutions (OTC: BLFS) Customer Completion Of HypoThermosol® Clinical Trial 0 comments
    Dec 12, 2012 8:35 AM

    HypoThermosol Utilized as Combination Biopreservation Medium and Vehicle Solution for Therapeutic Cells

    BLFS' customer TiGenix NV (Euronext Brussels: TIG) has completed a PI clinical safety trial of its expanded adipose-derived stem cell platform incorporating BioLife's cGMP HypoThermosol cell/tissue storage/shipping medium.

    The clinical trial, titled "PI Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs),"assessed the safety, tolerability and feasibility of a potential cell-based therapy TiGenix is developing for a number of autoimmune disorders including rheumatoid arthritis.

    The Bottom Line: HypoThermosol allows TIG to increase the stability profile of its clinical cell-based products and extend their shelf-life … the key in the commercial distribution. I have continually … touted BLFS as a "BUY" opportunity. It has enjoyed its recent joys of growth spurts and its sorrow in profit taking by day trader and investors - a market made timing for traders. BLFS closed at $0.30 in a day's range of $0.30 to $0.30 with only 600 share volume. I continue to reiterate this as a "BUY" on <these> downdraft … still sticking to BLFS being under-valued -with a target of $0.50 by years end since the stock has already visited $0.45 on 11/23/12. I could foresee a $0.05 to $0.10 rise based on the thinly traded activity of the stock many times without a news stimulus.

    TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.